Thr417
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr417  -  TNF-R1 (human)

Site Information
RtPRREAtLELLGRV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 11077252

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 3 , 4 , 5 ) , mutation of modification site ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PKACA (human) ( 1 )

Downstream Regulation
Effects of modification on TNF-R1:
molecular association, regulation ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
apoptosis, induced ( 1 ) , signaling pathway regulation ( 1 )
Inhibit interaction with:
GRB2 (human) ( 1 )

References 

1

Hapil FZ, et al. (2020) Negative Regulation of TNFR1 Signaling Via PKA-Mediated Phosphorylation of TNFR1. J Interferon Cytokine Res
32159413   Curated Info

2

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

3

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

4

Possemato A (2009) CST Curation Set: 7316; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST]
Curated Info

5

Possemato A (2009) CST Curation Set: 7317; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST]
Curated Info